Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Cigna GroupWBO:CIGN -0.39%60 3-Year EBITDA Growth Rate is 3.50% as of Mar. 2026, which is 59% below its 10-year median of 8.60. GuruFocus rates WBO:CIGN with a GF Score™ of 60/100 and a GF Value™ of €370.31 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 16 Healthcare Plans companies, The Cigna Group ranks better than 56.25% on this metric.
During the past 12 months, The Cigna Group's average EBITDA Per Share Growth Rate was 22.90% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 3.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -1.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of The Cigna Group was 41.90% per year. The lowest was -12.10% per year. And the median was 8.60% per year.
The Cigna Group (WBO:CIGN) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
The Cigna Group 3-Year EBITDA Growth Rate Related Terms
WBO:CIGN vs ELV, HUM, CNC: 3-Year EBITDA Growth Rate Comparison
For the Healthcare Plans subindustry, The Cigna Group's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Cigna Group 3-Year EBITDA Growth Rate vs Healthcare Plans Industry
For the Healthcare Plans industry and Healthcare sector, The Cigna Group's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where The Cigna Group's 3-Year EBITDA Growth Rate falls into.
The Cigna Group 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 3.50% mean?
The Cigna Group (WBO:CIGN) has a 3-Year EBITDA Growth Rate of 3.50% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for The Cigna Group and its competitors. This is 59% below median its historical median of 8.60. According to the industry distribution chart, The Cigna Group ranks #7 out of 16 companies in the Healthcare Plans industry, placing it in the top 43.7%.
Is The Cigna Group's 3-Year EBITDA Growth Rate too high?
The Cigna Group's current 3-Year EBITDA Growth Rate of 3.50% is 59% below median its 10-year median of 8.60. Based on the distribution chart, The Cigna Group ranks #7 out of 16 companies in the Healthcare Plans industry, which is above the industry midpoint. Overall, The Cigna Group has a GF Score™ of 60/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Cigna Group's 3-Year EBITDA Growth Rate compare to ELV and HUM?
According to the Healthcare Plans industry distribution chart, The Cigna Group ranks #7 out of 16 companies for 3-Year EBITDA Growth Rate. This puts The Cigna Group in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Plans company?
A good 3-Year EBITDA Growth Rate depends on the Healthcare Plans industry context. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for The Cigna Group and its competitors. The Cigna Group's current 3-Year EBITDA Growth Rate is 3.50%, which is 59% below median its own 10-year median of 8.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Cigna Group stock overvalued right now?
Based on GuruFocus' analysis, The Cigna Group (WBO:CIGN) is currently considered Significantly Undervalued. The stock's GF Value™ is €370.31, compared to a current price of €253.60 — trading 31.5% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 3.50%, which is 59% below median its 10-year median of 8.60. The Cigna Group's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For The Cigna Group (WBO:CIGN), the current 3-Year EBITDA Growth Rate is 3.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Cigna Group (WBO:CIGN) Overvalued in 2026?
Based on GuruFocus' analysis, The Cigna Group stock appears to be undervalued.
The current stock price of €253.60 is trading 31.5% below its estimated GF Value™ of €370.31.
GuruFocus considers The Cigna Group to be Significantly Undervalued.
Key valuation signals for WBO:CIGN:
3-Year EBITDA Growth Rate: 3.50% (59% below median its 10-year median of 8.60)
GF Value™: €370.31 vs. price of €253.60 (31.5% below fair value)
No single metric tells the full story. See the WBO:CIGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is with the Department of Defense, and it recently won a multiyear deal with top-tier insurer Centene. In health insurance and other benefits, Cigna primarily serves employers through self-funding arrangements, and the company operates mostly in the US with 16 million US and 2 million international medical members covered as of December 2025.
60GF Score
Get the complete analysis for WBO:CIGN
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:CIGN has been successfully added to your 
